Stockreport

Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF — SEP-363856 offers an innovative approach to the treatment of schizophrenia including the potential to be the first agent for the treatment of schizophr [Read more]